A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Latest Information Update: 02 Jun 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Interferon alpha-2b; Interferon alpha-2b; Ipilimumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms SWOG 1404
Most Recent Events
- 13 Mar 2025 Planned End Date changed from 23 Jan 2025 to 23 Jan 2026.
- 04 Jun 2024 Results (n=82) of exploratory analysis assessing the association between the presence of ctDNA after definitive surgical resection and RFS in pts with stage III melanoma treated with adjuvant immunotherapy presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 23 May 2024 According to a Natera media release, data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024.